Log in

IMMURON LTD/S Stock Price, Forecast & Analysis (NASDAQ:IMRN)

-0.01 (-0.28 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
Now: $3.51
50-Day Range
MA: $3.22
52-Week Range
Now: $3.51
Volume6,800 shs
Average Volume25,626 shs
Market Capitalization$12.57 million
P/E RatioN/A
Dividend YieldN/A
Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMRN



Sales & Book Value

Annual Sales$1.71 million
Book Value$1.47 per share



Market Cap$12.57 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.

IMMURON LTD/S (NASDAQ:IMRN) Frequently Asked Questions

What is IMMURON LTD/S's stock symbol?

IMMURON LTD/S trades on the NASDAQ under the ticker symbol "IMRN."

Has IMMURON LTD/S been receiving favorable news coverage?

Headlines about IMRN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IMMURON LTD/S earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for IMMURON LTD/S.

Who are some of IMMURON LTD/S's key competitors?

What other stocks do shareholders of IMMURON LTD/S own?

Who are IMMURON LTD/S's key executives?

IMMURON LTD/S's management team includes the folowing people:
  • Mr. Peter Anastasiou, Exec. Vice Chairman (Age 59)
  • Dr. Jerry Kanellos Ph.D., Chief Operating Officer (Age 58)
  • Dr. Gary S. Jacob, CEO & Director (Age 72)
  • Mr. Phillip Allen Hains, CFO & Company Sec. (Age 60)
  • Mr. David Lyon, Head of Marketing


(IMRN) raised $6 million in an initial public offering on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

How do I buy shares of IMMURON LTD/S?

Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IMMURON LTD/S's stock price today?

One share of IMRN stock can currently be purchased for approximately $3.51.

How big of a company is IMMURON LTD/S?

IMMURON LTD/S has a market capitalization of $12.57 million and generates $1.71 million in revenue each year. View Additional Information About IMMURON LTD/S.

What is IMMURON LTD/S's official website?

The official website for IMMURON LTD/S is http://www.immuron.com.au/.

How can I contact IMMURON LTD/S?

IMMURON LTD/S's mailing address is 62 LYGON STREET LEVEL 3, CARLTON C3, 3053. The company can be reached via phone at 610398245254 or via email at [email protected]

MarketBeat Community Rating for IMMURON LTD/S (NASDAQ IMRN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about IMMURON LTD/S and other stocks. Vote "Outperform" if you believe IMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel